Company Website:
http://www.aezsinc.com
CHARLESTON, S.C. -- (Business Wire)
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS):
All dollar amounts are stated in US$
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) announced
today that it has commenced a new “at-the-market” offering pursuant to
its existing At Market Issuance (“ATM”) Sales Agreement, dated April 1,
2016, with H.C. Wainwright & Co., LLC (the “Sales Agent”), under which
the Company may, at its discretion, from time to time during the term of
the ATM Sales Agreement, sell up to a maximum of 3,000,000 common shares
through ATM issuances on the NASDAQ Stock Market, up to an aggregate
amount of $9.0million. Any sales made under this ATM program
will be made through the Sales Agent. The common shares will be sold at
market prices prevailing at the time of the sale of the common shares
and, as a result, sale prices may vary.
The common shares will be offered under a new prospectus supplement no.
3 filed with the United States Securities and Exchange Commission (the
“SEC”) under the Company’s shelf registration statement on Form F-3
(333-194547) filed with the SEC on March 14, 2014, which was declared
effective by the SEC on March 28, 2014.
The shelf registration statement on Form F-3 and the prospectus
supplement for this offering are available on the SEC’s website (www.sec.gov).
Alternatively, the Sales Agent will provide copies of these documents
upon request by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue,
4th Floor, New York, NY 10022 at placements@hcwco.com.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the common shares,
nor shall there be any sale of the common shares in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such
state or jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel treatments in oncology,
endocrinology and women’s health. We are engaged in drug development
activities and in the promotion of products for others. We recently
completed Phase 3 studies of two internally developed compounds. The
focus of our business development efforts is the acquisition of licenses
to products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in non-U.S. territories where such out-licensing
would enable us to ensure development, registration and launch of our
product candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006509/en/
Contacts:
Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior
Vice President
ir@aezsinc.com
Source: Aeterna Zentaris Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.